BCRX Earnings & Financial Statements
BioCryst Pharmaceuticals, Inc.
$8.05
-$0.02(-0.25%)
39
Overall
60
Value
10
Tech
47
Quality
Market Cap
$2.06B
Volume
5.64M
52W Range
$6.00 - $11.22
Target Price
$20.45
BCRX earnings and financial statements: BioCryst Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BCRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $874.84M | $450.71M | $331.41M | $270.83M | $157.17M |
| Cost of revenue | $19.07M | $12.27M | $4.48M | $6.59M | $7.26M |
| Operating income | $340.99M | -$2.54M | -$103.71M | -$148.44M | -$177.72M |
| EBITDA | $347.65M | $12.81M | -$116.33M | -$145.63M | -$67.54M |
| Net income | $263.86M | -$88.88M | -$226.54M | -$247.12M | -$184.06M |
| EPS (diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $514.16M | $490.42M | $516.96M | $550.00M | $588.15M |
| Total liabilities | $633.31M | $966.35M | $972.49M | $844.60M | $695.14M |
| Shareholders’ equity | -$119.15M | -$475.93M | -$455.53M | -$294.60M | -$106.99M |
| Cash and equivalents | $89.74M | $104.71M | $110.64M | $304.77M | $504.39M |
| Long-term debt | $10.01M | $324.92M | $314.47M | $237.43M | $142.04M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $347.37M | -$52.02M | -$95.14M | -$161.85M | -$142.16M |
| Capital expenditure | -$1.92M | -$1.12M | -$2.17M | -$1.35M | -$2.38M |
| Free cash flow | $344.90M | -$53.14M | -$97.31M | -$163.20M | -$144.54M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BCRX | $8.05 | -0.2% | 5.64M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get BioCryst Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW